

# \$2.2M Awarded to Collaboration Researching Rare Form of Ovarian Cancer

 JULY 14, 2020
  BY DAVID MELAMED
  IN NEWS.



A research collaboration led by the [Hudson Institute of Medical Research](#) as been awarded a \$2.2-million grant to advance knowledge about [ovarian granulosa cell tumors \(GCT\)](#) and ultimately improve the outcomes of patients with this rare form of [ovarian cancer](#). The multi-faceted research project will focus on mapping genetic mutations in GCTs, as well as developing better testing, finding gaps in patient data and care, and investigating personalized and combination treatment options. The five-year grant from the [Medical Research Future Fund's](#) Emerging Priorities and Consumer Driven Research Initiative is part of an Australian effort to fund [breakthrough research on ovarian cancer](#). GCT is a rare form of ovarian cancer that can occur at any age, and accounts for 5%–10% of all ovarian cancer cases. In most cases, GCTs are slow-growing and easy to detect and treat, though they can return up to 30 years later as more resistant and aggressive cancers. In a small percentage of GCT patients, however, the cancer appears at younger ages (before 30) and is very aggressive from the start. Researchers at the Hudson Institute, [Monash Health](#), [Deakin University](#), and [The Walter and Eliza Hall Institute of Medical Res](#)

[Subscribe](#) or [log in](#) to access all post and page content.